Buprenorphine-Naloxone Found More Effective Than Extended-Release Naltrexone In Preventing Non-Fatal Opioid Overdoses Following Withdrawal Treatment

Adults with opioid use disorder who received buprenorphine-naloxone following medically managed opioid withdrawal treatment experienced fewer non-fatal opioid overdoses than those treated with extended-release (XR) naltrexone, according to a comparative effectiveness analysis. The study compared all-cause mortality and non-fatal opioid overdoses among adults following discharge from medically managed opioid withdrawal treatment.

The analysis followed 36,752 unique individuals across 106,052 discharge episodes and assessed outcomes over a 24-week follow-up period. Within 28 days after discharge, 13.4% of individuals initiated buprenorphine-naloxone treatment, while 4.5% initiated XR naltrexone. The adjusted cumulative . . .